ArticleJournal of cardiothoracic surgery2026
Preoperative MELD score variants and survival trajectories following in acute type A aortic dissection with follow‑up up to three years.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute type A aortic dissection (ATAAD) remains a life-threatening cardiovascular emergency with substantial perioperative risk. Conventional cardiac risk scores often fail to capture acute multi-organ dysfunction, limiting their predictive value in emergent settings. The Model for End-Stage Liver Disease (MELD) and its variants may provide a rapid laboratory-based approach for risk stratification in ATAAD. Originally developed for hepatic disease, MELD could reflect systemic derangements relevant in ATAAD.
methodsWe retrospectively analyzed 510 ATAAD patients undergoing emergency surgery (2000-2019). MELD-I, MELD-Na (sodium-adjusted), and MELD-XI (excluding INR) were calculated from admission labs and compared with the Charlson Comorbidity Index (CCI). The primary endpoints were in-hospital mortality and 3-year all-cause mortality. Statistical analyses included receiver operating characteristics (ROC) curves, DeLong tests, multivariable logistic regression, and Kaplan-Meier survival analysis (p < 0.05).
resultsIn-hospital mortality was 17%. MELD-I was independently associated with in-hospital mortality and showed better discriminatory performance than CCI in this cohort. (AUC 0.642 vs. 0.502; p = 0.0002). Mortality increased stepwise across MELD-I categories. Kaplan-Meier analysis demonstrated significant differences in 3-year survival (log-rank p < 0.001), with female patients showing worse outcomes (p = 0.0052).
conclusionsThe MELD-I score enables rapid, lab-based assessment of acute organ dysfunction and may perform better traditional comorbidity indices for predicting early mortality in ATAAD. While its long-term prognostic value appears limited, MELD-based stratification may still provide practical support for emergency risk assessment. The observed sex-specific survival difference should be interpreted cautiously and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.